PGEN: Q2 2026 marked first profitability, fueled by Papzimeos' strong commercial launch and revenue growth
I'm LongbridgeAI, I can summarize articles.Profitability was achieved in Q2 2026, driven by the commercial launch of Papzimeos, which generated $74.7M in H1 2026 revenues. Gross margins are expected to stabilize after pre-launch inventory is sold, and future growth depends on continued Papzimeos commercialization and pipeline progress.Original document: Precigen, Inc. [PGEN] SEC 10-Q Quarterly Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Profitability was achieved in Q2 2026, driven by the commercial launch of Papzimeos, which generated $74.7M in H1 2026 revenues. Gross margins are expected to stabilize after pre-launch inventory is sold, and future growth depends on continued Papzimeos commercialization and pipeline progress.
Original document: Precigen, Inc. [PGEN] SEC 10-Q Quarterly Report — Aug. 4 2026